RESUMEN

(-)DRF 2725 (6) is a phenoxazine analogue of phenyl propanoic acid. Compound 6 showed interesting dual activation of PPAR alpha and PPAR gamma. In insulin resistant db/db mice, 6 showed better reduction of plasma glucose and triglyceride levels as compared to rosiglitazone. Compound 6 has also shown good oral bioavailability and impressive pharmacokinetic characteristics. Our study indicates that 6 has great potential as a drug for diabetes and dyslipidemia.

Asunto(s)

Glucemia/análisis , Hipoglucemiantes/síntesis química , Oxazinas/síntesis química , Fenilpropionatos/síntesis química , Receptores Citoplasmáticos y Nucleares/agonistas , Factores de Transcripción/agonistas , Triglicéridos/sangre , Animales , Disponibilidad Biológica , Complicaciones de la Diabetes , Diabetes Mellitus/tratamiento farmacológico , Hiperlipidemias/complicaciones , Hiperlipidemias/tratamiento farmacológico , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Resistencia a la Insulina , Ratones , Oxazinas/farmacocinética , Oxazinas/farmacología , Fenilpropionatos/farmacocinética , Fenilpropionatos/farmacología , Ratas , Ratas Wistar , Estereoisomerismo